Kringle Pharma (TSE:4884) Other Current Liabilities: 円321.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
41 GF Score
Price 円317.00
GF Value 円488.73
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Other Current Liabilities?

Kringle Pharma TSE:4884 -0.63% 41 Other Current Liabilities is 円321.12 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 41/100 and a GF Value™ of 円488.73 (Possible Value Trap). The stock has 5 warning signs investors should review.

Kringle Pharma's other current liabilities for the quarter that ended in Mar. 2026 was 円321.12 Mil.

Kringle Pharma's quarterly other current liabilities declined from Sep. 2025 (円87.54 Mil) to Dec. 2025 (円74.19 Mil) but then increased from Dec. 2025 (円74.19 Mil) to Mar. 2026 (円321.12 Mil).

Kringle Pharma's annual other current liabilities increased from Sep. 2023 (円35.90 Mil) to Sep. 2024 (円90.24 Mil) but then declined from Sep. 2024 (円90.24 Mil) to Sep. 2025 (円87.54 Mil).

Kringle Pharma Other Current Liabilities Related Terms

Kringle Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Other Current Liabilities Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial 94.74 108.47 35.90 90.24 87.54

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.30 28.76 87.54 74.19 321.12
TSE:4884
41GF Score
Kringle Pharma Inc TSE:4884
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円321.12 Mil mean?
Kringle Pharma (TSE:4884) has a Other Current Liabilities of 円321.12 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kringle Pharma.
Is Kringle Pharma's Other Current Liabilities too high?
Kringle Pharma's current Other Current Liabilities is 円321.12 Mil. Overall, Kringle Pharma has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Other Current Liabilities compare to VRTX and REGN?
Kringle Pharma's Other Current Liabilities of 円321.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kringle Pharma. Kringle Pharma's current Other Current Liabilities is 円321.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円488.73, compared to a current price of 円317.00 — trading 35.1% below its estimated fair value. The current Other Current Liabilities is 円321.12 Mil. Kringle Pharma's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Other Current Liabilities is 円321.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円317.00 is trading 35.1% below its estimated GF Value™ of 円488.73. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Other Current Liabilities: 円321.12 Mil
  • GF Value™: 円488.73 vs. price of 円317.00 (35.1% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
41GF Score

Get the complete analysis for TSE:4884

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円317.00
Price
円488.73
GF Value